Search results for "clinical trials as topic"

showing 10 items of 313 documents

Double-blind cross-over study with oral alpha-ketoacids in patients with chronic renal failure.

1980

In 15 ambulatory patients with renal insufficiency (creatinine clearance, 9.9 +/- 3.0 ml/min) the effect of oral supplementation with alpha-ketoacids has been compared with that of placebo. The protein intake amounted to 0.55 g protein per kilogram body weight of high biological value, as estimated by dietary recordings. After a control period of 3 months the patients received, in a double-blind study, 1.05 g alpha-ketoacids/10 kg body weight per day or a placebo for 6 weeks with a subsequent cross-over. Fasting blood samples were analyzed at 3-week intervals for routine laboratory parameters and 17 proteins. Anthropometric and clinical data have been recorded every 3 weeks. While therapy w…

AdultMalemedicine.medical_specialtyMedicine (miscellaneous)Renal functionAlpha (ethology)PlaceboGastroenterologyPhosphatesPlacebosElectrolytesDouble-Blind MethodInternal medicinemedicineHumansClinical Trials as TopicNutrition and Dieteticsbusiness.industrynutritional and metabolic diseasesBiological valueBlood ProteinsAnthropometryMiddle AgedCrossover studyKeto AcidsDietClinical trialEndocrinologyCreatinineAmbulatoryKidney Failure ChronicFemalebusinessThe American journal of clinical nutrition
researchProduct

Natalizumab: a country-based surveillance program

2008

Natalizumab is a humanized monoclonal antibody with a selective adhesion-molecule inhibitor effect, and a demonstrated efficacy in decreasing the frequency of relapses and progression of disability in relapsing-remitting multiple sclerosis (RR MS). After the approval of FDA and EMEA in MS cases unresponsive to immunomodulating therapy or in severe MS patients also not previously treated with interferons, and considering the concern on the possible side effects, an accurate program of surveillance was organized in our country by a combined effort of AIFA, Cineca, Department of Pharmacology of University of Bologna, and a group of neurologists appointed by the National Society of Neurology (S…

AdultMalemedicine.medical_specialtyNeurologyDatabases FactualDrug-Related Side Effects and Adverse ReactionsNational Health ProgramsDrug ResistanceDermatologyDiseaseAntibodies Monoclonal HumanizedNatalizumabInternal medicineOutcome Assessment Health CareMultiple SclerosiPharmacovigilanceProduct Surveillance PostmarketingmedicineAdverse Drug Reaction Reporting SystemsHumansImmunologic FactorsMULTIPLE SCLEROSISNATALIZUMABClinical Trials as Topicbusiness.industryMultiple sclerosisAntibodies MonoclonalMean ageGeneral Medicinemedicine.diseasePsychiatry and Mental healthItalyREGISTRYPHARMACOVIGILANCEPhysical therapyFemaleSettore MED/26 - NeurologiaNeurology (clinical)NeurosurgerybusinessPreviously treatedFollow-Up Studiesmedicine.drug
researchProduct

Interferon as treatment for acute hepatitis C

1996

The efficacy of short-course (three months), low-dose (3 million units three times a week) interferon as treatment for acute hepatitis C was evaluated in a meta-analysis of controlled trials. Nine studies (five randomized and four nonrandomized) found by MEDLINE search were eligible for analysis. The outcomes assessed were the rate of patients with normal serum aminotransferases (all trials) and without HCV RNA in blood (five trials) after posttreatment follow-up. Eight trials compared interferon to no treatment, and one compared different schedules of interferon. The methodological quality of the studies was high. However, all trials had been planned for a short-term evaluation based on bi…

AdultMalemedicine.medical_specialtyPhysiologymedicine.medical_treatmentHepacivirusGastroenterologyInterferonInternal medicinemedicineHumansClinical significanceProspective cohort studyHepatologybusiness.industryGastroenterologyInterferon-alphaInterferon-betaImmunotherapyMiddle AgedHepatologyHepatitis CConfidence intervalMeta-analysisAcute DiseaseImmunologyRNA ViralFemaleControlled Clinical Trials as TopicAcute hepatitis CViral diseasebusinessmedicine.drugDigestive Diseases and Sciences
researchProduct

Urinary metabolites of histamine and leukotrienes before and after placebo-controlled challenge with ASA and food additives in chronic urticaria pati…

2002

Background: The recovery of mediator metabolites from urine has the potential to provide a rapid, safe, and easily available index of release of mediators. We aimed to determine urinary metabolites of both histamine and leukotrienes (LTs) in patients affected by chronic urticaria (CU). Methods: Twenty patients with CU were studied. They were selected on the basis of double-blind placebo-controlled challenge (DBPC) with acetyl salicylic acid (ASA) and food additives. Ten patients (group B) were negative to both challenges. Ten patients (group C) presented urticaria and/or the appearance of angioedema during or 24 h after challenge, with reactions to ASA (five patients) or food additives (fiv…

AdultMalemedicine.medical_specialtyTime FactorsUrticariaUrinary systemImmunologyMethylhistamineProvocation testAdministration OralUrinePlaceboGastroenterologyBronchoconstrictor AgentsDrug HypersensitivityExcretionchemistry.chemical_compoundDouble-Blind MethodSodium BenzoateInternal medicineSodium GlutamatemedicineHumansSulfitesImmunology and AllergyCyclooxygenase InhibitorsTartrazineLeukotriene E4CreatinineAspirinDose-Response Relationship DrugAngioedemabusiness.industryMethylhistaminesMiddle AgedEndocrinologyItalychemistryChronic DiseaseFemaleFood AdditivesControlled Clinical Trials as Topicmedicine.symptombusinessBiomarkersAllergy
researchProduct

Treatment with essential amino acids in patients on chronic hemodialysis: a double blind cross-over study.

1978

Patients on chronic hemodialysis may suffer from a latent protein deficiency, and therapy with essential amino acids has been recommended. In a double blind cross-over study, 13 hemodialysis patients received orally 15.7 g of essential amino acids daily over a 3-month period. Patients were on a liberal diet, containing 1 g of protein per kilogram of body weight per day. Hemodialysis was adequate. Therapy resulted in an increase in urea, uric acid, C3 c complement factor and a fall in C4. Lysine levels increased and phenylalanine fell. Malnutrition could not account for the observed metabolic changes, which are more likely due to uremic metabolic disturbances. A liberal diet of 1 g of protei…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentMedicine (miscellaneous)PhenylalanineComplement factor Ichemistry.chemical_compoundGlomerulonephritisRenal DialysisInternal medicineProtein DeficiencyMedicineHumansPrealbuminchemistry.chemical_classificationClinical Trials as TopicNutrition and DieteticsPyelonephritisbusiness.industryTransferrinComplement C3Middle Agedmedicine.diseaseCrossover studyAmino acidRetinol-Binding ProteinsMalnutritionEndocrinologychemistryBiochemistryUreaUric acidFemaleHemodialysisAmino Acids EssentialbusinessThe American journal of clinical nutrition
researchProduct

Soothing the seizures of children.

2008

Endocannabinoids are versatile molecules, regulating a variety of functions in the body. Daniele Piomelli explores how recent clinical trials testing rimonabant, an inhibitor of endocannabinoid signaling, for weight loss emerged from studies of individuals with schizophrenia; such trials have spurred basic research into how endocannabinoids affect both energy use and mood. Beat Lutz and Krisztina Monory examine how rimonabant might prove useful for preventing the development of adult epilepsy in response to fever-induced seizures in infants and young children.

AdultModels NeurologicalGeneral Biochemistry Genetics and Molecular BiologySeizures FebrileEpilepsyRimonabantPiperidinesBasic researchWeight lossCannabinoid Receptor ModulatorsmedicineHumansCannabinoid Receptor AntagonistsClinical Trials as TopicEpilepsybusiness.industryGeneral Medicinemedicine.diseaseEndocannabinoid systemClinical trialMoodChild PreschoolCannabinoid receptor antagonistPyrazoleslipids (amino acids peptides and proteins)medicine.symptomRimonabantbusinessNeurosciencemedicine.drugNature medicine
researchProduct

Rabbit anti-thymocyte globulin in liver transplantation: All that glitters is not gold, but 1000 patients are so many to dazzle

2012

AdultPathologymedicine.medical_specialtyBiopsymedicine.medical_treatmentLiver transplantationEnd Stage Liver DiseaseRecurrenceBiopsyAnimalsHumansMedicineAntilymphocyte SerumClinical Trials as TopicTransplantationHepatologymedicine.diagnostic_testbusiness.industryCase-control studyEnd stage liver diseaseHepatitis CMiddle Agedmedicine.diseaseHepatitis CLiver TransplantationAnti-thymocyte globulinCase-Control StudiesImmunologySurgeryRabbitsbusinessImmunosuppressive AgentsLiver Transplantation
researchProduct

Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey.

2011

Purpose: To use the Hunter Outcome Survey, an international database, to assess the safety and effectiveness of enzyme replacement therapy with idursulfase in patients with Hunter syndrome who started treatment before 6 years of age. Methods: The study population included all patients enrolled in the Hunter Outcome Survey who started idursulfase infusions (0.5 mg/kg every other week) before 6 years of age and who had at least one follow-up examination recorded. Results: The study population included 124 patients, younger than 6 years, who had a mean age at start of idursulfase of 3.6 ± 1.6 years (mean ± SD). The mean duration of treatment was 22.9 ± 14.6 months. A total of 69 infusion-relat…

AdultPediatricsmedicine.medical_specialtyAdolescentDatabases FactualIdursulfaseUrineIduronate Sulfatasechemistry.chemical_compoundYoung AdultInternational databaseMedicineHumansEnzyme Replacement TherapyYoung adultChildInfusions IntravenousGenetics (clinical)GlycosaminoglycansMucopolysaccharidosis IICreatinineClinical Trials as Topicbusiness.industryData CollectionInfantHunter syndromeEnzyme replacement therapymedicine.diseaseTreatment OutcomechemistryChild PreschoolPopulation studybusinessmedicine.drugGenetics in medicine : official journal of the American College of Medical Genetics
researchProduct

Immunologic diseases and brain tumors

2010

To do a bibliographic review of the given association of atopic [AD] and immunological diseases with central nerve system tumors [CNST] described a few years ago and to know the knowledge available. It gives an overview of the studies describing this association, and those explaining its mechanism. A negative association of AD with CNST stands out in case-control studies, which is not observed in cohort studies. The greatest association is seen for gliomas and is less significant for meningiomas. A clearer definition for the AD under study, tumour types, and the exact biochemical and clinical parameters to help diagnoses are the recommended as well as to establish an aetiologic and temporal…

AdultRiskPathologymedicine.medical_specialtyImmunologyMEDLINENegative associationBioinformaticsCohort StudiesImmunologic diseasesImmunology and AllergyMedicineAnimalsHumansChildPharmacologyClinical Trials as Topicbusiness.industryMechanism (biology)Brain NeoplasmsCase-control studyImmunityGeneral MedicineUnited StatesEuropeImmune System DiseasesCase-Control StudiesImmunological diseasesCentral nerve systembusinessCohort study
researchProduct

Does the diagnosis center influence the prognosis of ovarian cancer patients submitted to neoadjuvant chemotherapy?

2015

To compare prognosis of advanced epithelial ovarian cancer (AEOC) patients based on where the first surgical assessment was performed.Retrospective analysis of primary AEOC patients was performed and three groups were formed based on where the decision of primary treatment was taken: Internal, if the decision was carried out at our Institution (PDS (Primary Debulking Surgery), I-IDS (Internal-Interval Debulking Surgery)) and Referred in case women were referred after neoadjuvant chemotherapy (NACT) from other Centers (R-IDS (Referred-Interval Debulking Surgery)).Among 573 AEOC, 279 (48.7%) were PDS and 294 (51.3%) IDS. In particular, 134 of 294 (45.6%) were R-IDS and 160 (54.4%) were I-IDS.…

AdultTertiary Care CenterCarcinoma Ovarian EpithelialDisease-Free SurvivalcytoreductionTertiary Care CentersOvarian cancerAntineoplastic Combined Chemotherapy ProtocolsHumansNeoplasms Glandular and EpithelialAgedNeoplasm StagingAged 80 and overOvarian NeoplasmsCytoreduction; Interval debulking surgery; Ovarian cancer; PrognosisClinical Trials as TopicAntineoplastic Combined Chemotherapy ProtocolOvarian NeoplasmMiddle AgedPrognosisNeoadjuvant TherapySettore MED/40 - GINECOLOGIA E OSTETRICIAinterval debulking surgeryFemaleprognosineoadjuvant chemotherapyHuman
researchProduct